OBJECTIVE: The measurement of alcohol consumption is an essential component of research in patients at risk for or infected with HIV. Daily estimation measures such as the Timeline Followback (TLFB) have been validated, yet the optimal time window and its performance in non-treatment-seeking medical clinic subjects and among those with HIV are not known. METHOD: In 1,519 HIV-infected and 1,612 uninfected men receiving medical care in general medical or infectious disease clinics, we compared the association between 7-, 14-, and 30-day TLFB reports, obtained via telephone, of alcohol consumption using Spearman's correlation coefficients. To evaluate agreement between 7-, 14-, and 30-day reports of heavy episodic drinking, we evaluated percent agreement, sensitivity, and kappa statistics, considering 30-day report as the gold standard. RESULTS: The estimated prevalence of heavy episodic drinking was progressively higher for longer TLFB intervals (7 days: 6.3%; 14 days: 8.0%; 30 days: 9.5%). Correlation coefficients with 30- day TLFB were higher for 14 days (.94) than for 7 days (.86) overall (p < .001) and among HIV-infected (.94 vs. .86, p < .001) and uninfected (.95 vs. .87, p < 001). Correlations were similar by HIV status. When considered overall and by HIV status, the sensitivity, percent agreement, and kappa statistics are better for heavy episodic drinking based on 14 days compared with 7 days. CONCLUSIONS: A TLFB for alcohol consumption of 14 days is preferable to 7 days for non-treatment-seeking patients in medical clinics with and without HIV infection when compared with 30 days.
OBJECTIVE: The measurement of alcohol consumption is an essential component of research in patients at risk for or infected with HIV. Daily estimation measures such as the Timeline Followback (TLFB) have been validated, yet the optimal time window and its performance in non-treatment-seeking medical clinic subjects and among those with HIV are not known. METHOD: In 1,519 HIV-infected and 1,612 uninfected men receiving medical care in general medical or infectious disease clinics, we compared the association between 7-, 14-, and 30-day TLFB reports, obtained via telephone, of alcohol consumption using Spearman's correlation coefficients. To evaluate agreement between 7-, 14-, and 30-day reports of heavy episodic drinking, we evaluated percent agreement, sensitivity, and kappa statistics, considering 30-day report as the gold standard. RESULTS: The estimated prevalence of heavy episodic drinking was progressively higher for longer TLFB intervals (7 days: 6.3%; 14 days: 8.0%; 30 days: 9.5%). Correlation coefficients with 30- day TLFB were higher for 14 days (.94) than for 7 days (.86) overall (p < .001) and among HIV-infected (.94 vs. .86, p < .001) and uninfected (.95 vs. .87, p < 001). Correlations were similar by HIV status. When considered overall and by HIV status, the sensitivity, percent agreement, and kappa statistics are better for heavy episodic drinking based on 14 days compared with 7 days. CONCLUSIONS: A TLFB for alcohol consumption of 14 days is preferable to 7 days for non-treatment-seeking patients in medical clinics with and without HIV infection when compared with 30 days.
Authors: R Scott Braithwaite; Kathleen A McGinnis; Joseph Conigliaro; Stephen A Maisto; Stephen Crystal; Nancy Day; Robert L Cook; Adam Gordon; Michael W Bridges; Jason F S Seiler; Amy C Justice Journal: Alcohol Clin Exp Res Date: 2005-07 Impact factor: 3.455
Authors: Kevin L Kraemer; Kathleen A McGinnis; Melissa Skanderson; Robert Cook; Adam Gordon; Joseph Conigliaro; Yujing Shen; David A Fiellin; Amy C Justice Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Robert L Cook; Kathleen A McGinnis; Kevin L Kraemer; Adam J Gordon; Joseph Conigliaro; Stephen A Maisto; Jeffrey H Samet; Stephen Crystal; David Rimland; Kendall J Bryant; R Scott Braithwaite; Amy C Justice Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: R S Braithwaite; J Conigliaro; M S Roberts; S Shechter; A Schaefer; K McGinnis; M C Rodriguez; L Rabeneck; K Bryant; A C Justice Journal: AIDS Care Date: 2007-04
Authors: Jeffrey H Samet; Debbie M Cheng; Howard Libman; David P Nunes; Julie K Alperen; Richard Saitz Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Stephen A Maisto; Joseph C Conigliaro; Adam J Gordon; Kathleen A McGinnis; Amy C Justice Journal: J Stud Alcohol Drugs Date: 2008-05 Impact factor: 2.582
Authors: Jennifer L Brown; Kelly S DeMartini; Jessica M Sales; Andrea L Swartzendruber; Ralph J DiClemente Journal: Curr HIV/AIDS Rep Date: 2013-12 Impact factor: 5.071
Authors: Daniel J Paulus; Charles Jardin; Jafar Bakhshaie; Carla Sharp; Steven Paul Woods; Chad Lemaire; Amy Leonard; Clayton Neighbors; Charles P Brandt; Michael J Zvolensky Journal: Addict Behav Date: 2016-07-21 Impact factor: 3.913
Authors: Anne Buu; Runze Li; Maureen A Walton; Hanyu Yang; Marc A Zimmerman; Rebecca M Cunningham Journal: Subst Use Misuse Date: 2014-03-06 Impact factor: 2.164
Authors: Rebecca B Hershow; H Luz McNaughton Reyes; Tran Viet Ha; Geetanjali Chander; Nguyen Vu Tuyet Mai; Teerada Sripaipan; Constantine Frangakis; David W Dowdy; Carl Latkin; Heidi E Hutton; Audrey Pettifor; Suzanne Maman; Vivian F Go Journal: Drug Alcohol Depend Date: 2020-06-10 Impact factor: 4.492
Authors: Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Breanne E Biondi; Maureen Desabrais; Thomas Lincoln; Daniel J Skiest; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731
Authors: Oghenowede Eyawo; Yanhong Deng; James Dziura; Amy C Justice; Kathleen McGinnis; Janet P Tate; Maria C Rodriguez-Barradas; Nathan B Hansen; Stephen A Maisto; Vincent C Marconi; Patrick G O'Connor; Kendall Bryant; David A Fiellin; E Jennifer Edelman Journal: Alcohol Clin Exp Res Date: 2020-09-19 Impact factor: 3.455
Authors: Rebecca B Hershow; H Luz McNaughton Reyes; Tran Viet Ha; Geetanjali Chander; Nguyen Vu Tuyet Mai; Teerada Sripaipan; Constantine Frangakis; David W Dowdy; Carl Latkin; Heidi E Hutton; Audrey Pettifor; Suzanne Maman; Vivian F Go Journal: PLoS One Date: 2020-10-16 Impact factor: 3.240